Home / Psoriasis / What’s old is new in topical psoriasis therapy

What’s old is new in topical psoriasis therapy

Key clinical point: A fixed combination of halobetasol and tazarotene formulated as a lotion proved successful in phase II and is now being evaluated in a large phase III study.

Major finding: An investigational fixed-combination lotion consisting of halobetasol propionate 0.01% and tazarotene 0.045% achieved scores of clear or almost clear in 53% of patients, significantly better than either component as monotherapy.

Data source: This phase II, double-blind, multicenter, vehicle-controlled, 8-week randomized clinical trial included 212 patients with moderate or severe plaque psoriasis.

Disclosures: The study was funded by Valeant Pharmaceuticals. The presenter reported serving as an investigator, advisor, and speaker for the company.

Full Article

About Dr. J. Kim

Dr Kim developed (and is continuing to develop) dermatology research news as we way from dermatologists to stay on top of the latest advances in the field of dermatology.

Check Also

A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-1)

Study Description Go to  Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Brief Summary: The purpose of this study is to evaluate the efficacy and safety of mirikizumab in participants with moderate to severe plaque psoriasis. Condition or disease Intervention/treatment Phase Psoriasis Drug: Mirikizumab Drug: Placebo Phase 3 …

Leave a Reply

Your email address will not be published. Required fields are marked *